UPDATE - UBS Initiates Coverage on Momenta Pharmaceuticals (MNTA) with a Neutral; Risk-Reward Appears Appropriately Priced
Tweet Send to a Friend
UPDATE - UBS initiates coverage on Momenta Pharmaceuticals (NASDAQ: MNTA) with a Neutral. PT $17.
UBS analyst says, "Given the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst says, "Given the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
